Venture Capital

NeuroSense adds world-renowned expert Prof. Steven Arnold to its board, a major vote of confidence in its multi-target Alzheimer's drug, PrimeC.

The LA Rams and energy firm CRC mark one year of a partnership to offset team emissions, but does this innovative, local-first model truly change the game?

Safi Biotherapeutics and ARMI | BioFabUSA achieve a critical step toward mass-producing red blood cells, offering hope for patients and military readiness.

Targa Exploration grows its El Zanjon project by 66% in a key gold district, signaling a major push to uncover a new discovery in Santa Cruz.

With a major cash infusion and key pipeline milestones, Xilio Therapeutics validates its tumor-activated approach to fighting cancer and extends its runway to 2027.

A new national reimbursement code for NeurAxis's IB-Stim therapy is set to revolutionize access for chronic GI pain patients, validating the technology.

After 30 years, CEO Jim Foster will retire, passing the torch to COO Birgit Girshick in a move that signals continuity and a new era of governance.

Klotho Neurosciences will present its novel gene therapy for Alzheimer's and ALS at a key summit, seeking to turn scientific promise into clinical reality.

Pan Global Resources has defined a major copper and gold resource in Spain, fueling the green energy transition and reviving a historic mining district.

858 Therapeutics' novel PARG inhibitor offers new hope for patients with a deadly, drug-resistant form of ovarian cancer, accelerating its path to approval.

With a potential winter drill program at its Tharsis REE project and high-grade results at Big Mack, the company is advancing two key Canadian assets.

With a key FDA meeting set, Trevi Therapeutics pushes its drug Haduvio into late-stage trials, offering hope for millions with no approved treatments.

With record growth and a fortified cash position, ElevateBio combines AI-driven discovery and industrial-scale manufacturing to power the gene therapy boom.

A new vectorized antibody therapy for ALS, VTx-002, has been granted FDA Fast Track status, accelerating its path to patients battling the disease.

Replicate Bioscience secures major funding to develop next-gen self-replicating RNA vaccines, aiming for more durable and accessible global health solutions.

AI data platform Protege raises its Series A to $65M, tackling the critical data bottleneck with an ethical, licensing-first model for real-world data.

Eurythmics legend Dave Stewart launches a new venture builder to give artists control over their IP and revenue. But can this "creativity-first" model work?

Westwater Resources heads to a key investor conference, carrying the weight of its Alabama graphite projects and the future of America's EV supply chain.

CN Energy's robotics arm, Pathenbot, just won a key "Investment-Ready" award at CES 2026. What does this reveal about its disruptive tech and global plans?

How a blend of private capital and pragmatic regulation is turning Singapore into a global hub for longevity research, pushing scientific and ethical boundaries.